G7 Acetabular System With Vivacit-E or Longevity Liner PMCF Study
← catalyst calendarNCT04754087 · readout in 2,691 d
Sponsored by Zimmer Biomet (industry) · ZBH — their whole pipeline →.
Phase
Not applicable
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
300estimated
Sites
11
Countries
Denmark, Netherlands, Sweden +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-07-07 | actual | When the study began enrolling |
| Primary completion | 2033-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2033-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2021-02-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Total Hip Arthroplasty
- Degenerative Joint Disease of Hip
- Avascular Necrosis of Hip
- Rheumatoid Arthritis of Hip
- Osteoarthritis, Hip
- Osteoarthritis of Hip
- Fractures, Hip
- Fracture of Hip
Intervention
- Device: Vivacit-E and Longevity (HXLPE) Liners
Primary outcomes
what the primary-completion date above is the date OFSurvival of the study device (liner); whether or not it is still implanted in the subject
measured At 10 years
Adverse Event (safety)
measured At 10 years
Permalink · ZBH's whole pipeline · Catalyst calendar · Every registered study · What changed